Indiebio Class Seven Demo Day | SOSV

IndieBio New York is hosting its first demo day of the year, on January 24, 2024.

The demo day will feature nine companies fresh out of IndieBio NY’s program (cohort #7) that are working on breakthrough innovations in climate-resilient agriculture, diagnostics, carbon & methane upcycling, cancer therapeutics, and more. TechCrunch recently published the companies with brief descriptions.

SOSV is a global venture capital firm that offers multi-stage investment, starting with pre-seed startup development programs. SOSV’s core mission is to fund visionary, deep tech founders who will have a profound impact on human and planetary health. As of September 2023, SOSV had $1.5 billion in assets under management.

SOSV’s startup development programs are the hard tech-oriented HAX and life sciences-driven IndieBio. Both offer deep tech founders critical technical, product, and company-building expertise in addition to well equipped lab and fabrication facilities.


SOSV’s most recent core fund is the $277 million Fund IV, which closed in 2019. In 2021, SOSV also raised a $100 million Select Fund to support the expansion of follow-on investing in SOSV’s portfolio.

SOSV’s limited partners include corporates, financial institutions, family offices, and high-net worth individuals from around the world, including Credit Suisse, Tiedemann Advisors, Davy Group, ZX Ventures (the strategic arm of Anheuser-Busch InBev), HP Ventures, and Sumitomo Corp. In SOSV’s Fund IV ($277 million), 50% of the limited partners are located in North America, 25% in Europe, and 20% in Japan and Southeast Asia.

SOSV founder and managing GP O’Sullivan has donated tens of millions in profits from his investments to charitable causes, including the Khan Academy, I-ASC and CoderDojo, as well as many other educational, autism-related and humanitarian efforts. As a firm, SOSV commits 10% of SOSV profits to charity. O’Sullivan resides in Princeton, NJ.